VivoSeq
Explore
Companies
Drugs
Sign In
Report Error
Invokana and
Approved
Small molecule
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
1
Indications
1
Total Trials
0
Active Trials
0
Competitors
Pipeline
Status by Indication
[3]
[1]
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
ESRD
Completed
Preclinical
Phase 1
Phase 2
Phase 3
Approved
ESRD
Approved
Completed
Clinical
Trials by Indication
[1]
ESRD
1 trial
Safety and Efficacy of Canagliflozin in Advanced CKD
Completed
·
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
·
Approved
·
NCT05309785
·
34 enrolled
Sources
References
[1]
ClinicalTrials.gov
—
1 trial record for Invokana and. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL
—
Invokana and compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform
—
Drug–disease associations for Invokana and. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR
—
McGill University Health Centre/Research Institute of the McGill University Health Centre company filings. U.S. Securities and Exchange Commission.
Details
Drug Info
Quick Facts
Modality
Small molecule
[2]
Highest Phase
Approved
[1]
Company
M
McGill University Health Centre/Research Institute of the McGill University Health Centre
Related News